Balancing the Risks and Benefits of Multidrug Regimens in the Clinical Management of Nontuberculous Mycobacterial Lung Disease.

Slides:

Advertisements

Similar presentations

Introduction. Adult ADHD in the Real World: From Clinical Trials to Clinical Practice.

Advertisements

Upfront Combination Therapy vs Step-Up Approach for PAH:

The Patient Experience With Systemic Lupus Erythematosus

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Endocrine Combinations in HR-Positive MBC: The Future Is Now

Diabetic Dyslipidemia in Practice

Engaging the INSULIN-TREATED T2DM Patient: the Importance of Real-World Data.

Monitoring and Management of Adult Relapsed/Refractory Acute Promyelocytic Leukemia.

Challenges and Opportunities in the Management of ANCA-Associated Vasculitis.

Strategies for the Management of EGFR TKI Resistance in Advanced NSCLC

Gout Management.

Pseudomonas Lung Infections in Cystic Fibrosis

Introduction. Clinical Pearls on the Management of Immune-Mediated Adverse Events Affecting the Endocrine System.

Moderate-Intensity Statins for Dyslipidemia: How to Treat Today?

Select Topics in Cardiovascular Medicine

Dual Bronchodilation in COPD: From Clinical Trial Evidence to Clinical Practice.

Hemophilia Updates: Incorporating New Concepts Into Practice

Clinical Presentations of VTEa,b NOACs VTE Acute Treatment Trials.

Optimizing the Treatment of Recurrent/Metastatic SCCHN

Optimizing Outcomes in the Management of GIST

Cost Effectiveness and Optimal Outcomes in HF

nAMD: Switching Therapies - what you need to know

Decision-making in the eRA of Treating to Target

Program Introduction. Monoclonal Antibodies and Immunogenicity: Relevance to Clinical Practice?

What Does the Primary Care Physician Need to Know About Chronic Hepatitis C?

Precision Management of RA and Comorbidities

Managing gBRCA-Positive Metastatic Breast Cancer

Case Study. Managing Medication and Adherence in SIHD: Partnering With the Patient to Improve Care.

The future of urate-lowering strategies for gout

Nontuberculous Mycobacterial Lung Disease

Evaluating Next-Generation BTK Inhibitors

Gene Therapy: Past, Present, and Future

Atopic Dermatitis. Introduction to a Clinical Course On New Developments In Atopic Dermatitis.

Patient Selection, Pharmacoeconomics, and PCSK9 Inhibitors

Immunotherapy for cSCC

Personalizing Management in the Care of Patients With Advanced Sarcoma

Clinicians' Corner in Dyslipidemia

Intro: Biomarkers in RA

When to Start and What to Use

The Road to Quality Improvement in HER2-Positive Breast Cancer

CMV in the HSCT Recipient

When Is Intrathecal Drug Delivery Appropriate?

Optimizing Insulin Therapy in Primary Care: Basal Plus Incretin Combinations.

Defining Patient-Centered Care: Spotlight on Advanced Non-Small Cell Lung Cancer.

Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: Considerations for Previously Treated Disease.

A Guideline-Based Approach to HCV Care

Are We Making Progress in the Management of Huntington Disease?

Optimizing Joint Health in Hemophilia

Challenges in LA SCCHN.

EXPERT INSIGHTS: IL-17 INHIBITION IN PSORIASIS CARE

Factor Xa Inhibitors in Coronary Artery Disease

Inhaled Antibiotics for Patients With CF in the Era of CFTR Modulators

Assessing the Burden of Hyperkalemia

THE CONTINUUM OF CARE IN mCRC: OPTIMIZING USE OF EGFR ANTIBODIES

When Is Intrathecal Drug Delivery Appropriate?

Optimizing Outcomes in mRCC: Finding the Balance of Immune Inhibition

Assessing the Burden of Hyperkalemia

CDK4/6 Inhibitors.

The Nurse View: Spotlight on EGFR-Mutated NSCLC

Championing Evidence-Based Care in Patients With Acute Low Back Pain

Introduction. Welcome to this program, titled De-Escalating Therapy in Epilepsy: A Return to Monotherapy.

Clinical Pearls in the Management of Patients With Advanced Non-Small Cell Lung Cancer.

The Building Blocks of Homocystinuria and Homocysteinemia Management

Exploring the Use of Adeno-Associated Virus for Gene Therapy

Expert Perspectives.

Rethinking Risk Stratification for Nonischemic HF:

Foundations of Asthma.

Disease Activity Cutoffs for ACR-Recommended RA Disease Activity Measure

What's New in NOACs in AF?.

Management of NTM Lung Disease

Presentation transcript:

Balancing the Risks and Benefits of Multidrug Regimens in the Clinical Management of Nontuberculous Mycobacterial Lung Disease

Program Overview

NTM Lung Disease Introduction

Radiographic Manifestations

Predisposing Factors

Managing NTM Lung Disease Can Be Challenging

Determining Who To Treat

Guideline-Based Recommendations for Treating NTM Lung Disease

Standard Treatment for MAC, Macrolide-Susceptible Disease

Standard Treatment for MAC, Macrolide-Susceptible Disease (cont)

When Is Treatment NOT Indicated?

Treatment-Related AEs Standard Care

Monitoring Response

Unresolved Questions

Unresolved Questions (cont)

Unresolved Questions (cont)

Benefits of Inhaled Therapies

ALIS Overview

Phase 2 Trial ALIS

Treatment-Related AEs ALIS vs Placebo

Findings ALIS Phase 2 Trial

Phase 3 Trial CONVERT

Findings CONVERT Trial

Treatment-Related AEs CONVERT Trial

Who Best Benefits From ALIS?

Bedaquiline Overview

Case Series Bedaquiline

Treatment-Related AEs Bedaquiline

Oxazolidinones Tedizolid, Linezolid Overview

Clofazimine Overview

Treatment-Related AEs Clofazimine

Nitric Oxide Overview

Concluding Remarks

Abbreviations